Picture EBD Group BioPharm America 2020 Digital Event BEU2020 650x81
Organisation › Details

Sanifit (Group)

Sanifit is a biopharmaceutical company focused on the development of SNF472. The company was founded in 2007 as a spin-off of the University of the Balearic Islands. SNF472 is an experimental drug for the treatment of cardiovascular diseases linked to calcification in the End Stage Renal Disease population undergoing hemodialysis. Sanifit has completed phase 1a studies with healthy volunteers in 2014. It is currently concluding a phase Ib/IIa study in hemodialysis patients. Following this series C funding round of $41.3M (€36.6M), Sanifit will start a phase IIb study in ESRD and extend the orphan program in calciphylaxis into phase II/III clinical trials. *


Period Start 2007-01-01 splitoff
Products Industry cardiovascular drug
  Industry 2 SNF472 (Sanifit)
Person Person Perelló, Joan (Sanifit 201509 CEO)
Region Region Palma de Mallorca
  Country Spain (España)
  City 07121 Palma de Mallorca, Islas Baleares
  Tel +34-971-439-925
    Address record changed: 2012-10-28
Basic data Employees n. a.
    * Document for �About Section�: Laboratoris Sanifit S.L.. (9/8/15). "Press Release: Sanifit Raises €36.6M ($41.3M) in Series C Financing Round". Berlin.
Record changed: 2019-05-30


Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for Sanifit (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px

» top